We are looking forward to packed days next week in Munich at #AIDS2024! Join IAVI for rich discussions on everything from why we still need at HIV vaccine, to how to accelerate progress on bnAbs for prevention, and even how to ensure inclusion of end-user perspectives in biomedical research. Please join us for a set of exciting sessions, which you can read about in full on our website. We're looking forward to seeing you there! https://lnkd.in/ezivDtwg
IAVI
Research Services
New York, NY 33,938 followers
Translating science into global health impact.
About us
Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.
- Website
-
www.iavi.org
External link for IAVI
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 1996
- Specialties
- AIDS vaccine, research and development, product development partnership, HIV/AIDS, vaccine development, global health, capacity strengthening, clinical trials, and scientific research
Locations
-
Primary
125 Broad St
9th Floor
New York, NY 10004, US
Employees at IAVI
Updates
-
We're #hiring a new Manager, Quality Systems in New York City Metropolitan Area. Apply today or share this post with your network.
-
We're #hiring a new Specialist, Grants, Contracts & Compliance in Gurgaon Rural, Haryana. Apply today or share this post with your network.
-
We're #hiring a new Administrative Associate, Clinical Development in New York City Metropolitan Area. Apply today or share this post with your network.
-
We're #hiring a new Associate Director, Global GCP Quality in South Africa. Apply today or share this post with your network.
-
Watch now! IAVI's Dr. Gaudensia Mutua and HJF Medical Research International's Dr. Abdulwasiu Bolaji Tiamiyu were recently interviewed by NTAi News about IAVI C105, the first #LassaFever vaccine candidate to enter a Phase 2 clinical trial. They discussed African scientists' and communities' leading roles in developing this vaccine – plus, how these efforts drive forward global health progress. ▶ https://lnkd.in/ey23GxM3 CEPI (Coalition for Epidemic Preparedness Innovations)
-
-
IAVI reposted this
🎉Keynote panel announcement! We're excited to announce another panel with more key speakers! This panel will explore the challenges and strategies related to the uptake of vaccines amidst rapid vaccine development. Our panelists are: ⭐Hanna Nohynek, Chief Physician, National Institute for Health and Welfare ⭐Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, European Medicines Agency ⭐Marion F. Gruber, Ph.D., MS, Vice President of Public Health and Regulatory Affairs, IAVI ⭐Thomas Waite, Deputy Chief Medical Officer, Department of Health and Social Care ⭐Sibilia Quilici, Executive Director, Vaccines Europe For speaking opportunities, apply here! https://buff.ly/45Tkd19 or get in touch with Anna (anna.hindley-skelt@terrapinn.com)💫 Want to see this keynote panel live? Register now! https://buff.ly/4eWoapE 📆Pre-Congress Workshops | 28 October 2024 📍Catalonia Barcelona Plaza 📆Main Congress | 29 – 31 October 2024 📍Fira de Barcelona Montjuic #WVCEU #VaccineDevelopment #VaccineInnovation #HealthcareInnovation #Vaccines
-
-
IAVI reposted this
Join us at the next TB Vaccine Advocacy Roadmap (TB Vax ARM) webinar on Tuesday 16 July to hear insights on: 💉 Inclusion of new TB vaccines in Gavi, the Vaccine Alliance Vaccine Investment Strategy ⏩ The World Health Organization's TB Vaccine Accelerator Council 🦠 Advocating for TB vaccines at the High-Level Meeting on AMR 🔗 Register at https://lnkd.in/eKSa7SXs
-
-
IAVI and our partners UNITAID, Medecins Patent Pool, and Wellcome are proud to announce a new publication providing insight into novel approaches that can expand access to monoclonal antibodies for those in low- and middle- income countries. https://lnkd.in/enVkPsF7
Unitaid, IAVI, Medicines Patent Pool, and Wellcome publish novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries
https://www.iavi.org
-
Saturday, July 6, is World Zoonoses Day! On this date in 1885, the first rabies vaccine was administered. This year, IAVI is marking progress toward a vaccine for a globally important zoonotic illness: Lassa fever. A new website feature highlights some recent publications and announcements marking some exciting steps forward: 🔵 An updated Lassa research roadmap in The Lancet co-authored by Swati Gupta, IAVI’s head of emerging infectious diseases. 🔵 The announcement of the start of vaccinations in a Phase 2 clinical trial of IAVI’s Lassa fever vaccine candidate in Liberia. 🔵 A commentary on African leadership in Lassa vaccine development by Dr. Gaudensia Mutua, a medical monitor on our Lassa trials. Read and share the feature to help IAVI and our partners celebrate these developments!👇 #globalhealth #lassafever #vaccineswork #partnerships #outsmartepidemics CEPI (Coalition for Epidemic Preparedness Innovations) | Global Health EDCTP3 | National Institute of Allergy and Infectious Diseases (NIAID) | Viral Hemorrhagic Fever Consortium | Batavia Biosciences
World Zoonoses Day 2024: IAVI celebrates progress in Lassa vaccine development
https://www.iavi.org